Clinical TrialJul 24, 2026, 08:51 AM
Autonomix Medical's Neural Sensing Platform Shows Positive Preclinical Results
AI Summary
Autonomix Medical, Inc. announced positive results from a preclinical study for its proprietary neural sensing platform. The study successfully demonstrated the platform's ability to detect, localize, and confirm changes in renal neural activity, providing direct physiological feedback before and after targeted ablation. These findings represent a critical milestone, supporting the continued development of the platform for physiology-guided renal denervation procedures, which currently lack direct physiological feedback. The company plans further preclinical and clinical studies.
Key Highlights
- Preclinical study demonstrated ability to detect, localize, and confirm changes in renal neural activity.
- Proprietary neural sensing platform identified neural signals along renal artery and surrounding tissue.
- Provided direct physiological feedback before and after targeted ablation.
- Observed attenuation of previously detected neural signals following targeted ablation.
- Findings support continued development of the platform for physiology-guided renal denervation.
- Technology aims to provide actionable neural sensing information to guide therapy.
- Company plans additional preclinical and future clinical studies.
Price Impact
More from AMIX